Yourgene Health PLC Testing service agreement with MyHealthCheckedplc (5495U)
April 06 2021 - 8:43AM
UK Regulatory
TIDMYGEN
RNS Number : 5495U
Yourgene Health PLC
06 April 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Testing service agreement with MyHealthChecked plc
Yourgene Genomic Services providing COVID-19 services to MHC's
new Boots partnership
Manchester, UK - 6 April 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that it has
signed a COVID-19 testing services agreement with its partner
MyHealthChecked plc (AIM: MHC) ("MyHealthChecked") to support their
newly announced partnership with Boots UK Limited ("Boots"), the
health and beauty retailer and pharmacy group. Through the service
agreement, a proportion of the MyHealthChecked(TM) COVID-19 tests
will be processed by Yourgene Genomic Services ("YGS") at the
Company's Citylabs 1.0 laboratory in Manchester, which is well
equipped to manage the increased demand. In addition, samples
processed at MHC's own laboratories are already using Yourgene's
Clarigene SARS CoV-2 PCR CE-IVD test kit.
The MyHealthChecked(TM) COVID-19 at-home nasal swab kit and PCR
laboratory testing service will be promoted online and in Boots
stores across Great Britain, allowing customers to take a nasal
swab themselves at home and send samples safely and securely via
the Royal Mail Tracked 24 service to be tested using established
laboratory-based PCR detection methods. Yourgene's Manchester based
laboratories will be used to undertake testing and results are
provided within 24-48 hours, via an online portal.
Volumes are unquantified at this stage until lockdown
restrictions ease. T he general testing and Fit to Fly service will
be launched online shortly and promoted across over 507 stores in
England, Wales and Scotland from April.
Lyn Rees, CEO of Yourgene Health and Non-Executive Director of
MyHealthChecked, commented: "I would like to congratulate
MyHealthChecked on this agreement with Boots and we look forward to
supporting their COVID-19 testing service and product supply to
their laboratory. COVID-19 PCR tests have become a travel essential
and as we anticipate the return of international travel later in
the year, we expect to see an increase in demand which we are well
positioned to deal with."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation. The Directors of the Company
take responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGREADLKELFFEFA
(END) Dow Jones Newswires
April 06, 2021 09:43 ET (13:43 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024